Trimethobenzamide

Aka: Trimethobenzamide, Tigan

advertisement

II. Indications

  1. Emesis of central causes

III. Dosing

  1. Adults: 250 mg PO or 200 mg IM/PR q6-8 hours
  2. Child (15 to 40 kg): 100-200 mg PO/PR tid to qid
  3. Child (<15 kg): 100 mg PR tid to qid
    1. Do not use in newborns

IV. Mechanism

  1. Centrally acting non-Phenothiazine Antiemetic

V. References

  1. Johnson (1993) Harriet Lane, Mosby, p. 521
  2. (2002) Tarascon Pocket Pharmacopoeia, p. 67

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Trimethobenzamide." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Cost: Medications

trimethobenzamide (on 4/19/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
TRIMETHOBENZAMIDE 300 MG CAP Generic $1.19 each
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information.

Ontology: trimethobenzamide (C0077163)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C100146
SnomedCT 14814001, 372657005
LNC LP19504-7, MTHU010019
English trimethobenzamide, trimethobenzamide [Chemical/Ingredient], TRIMETHOBENZAMIDE, Trimethobenzamide, Trimethobenzamide (product), Trimethobenzamide (substance)
Spanish trimetobenzamida (producto), trimetobenzamida (sustancia), trimetobenzamida
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Tigan (C0733768)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C100146
English Tigan, tigan, Monarch brand of trimethobenzamide monohydrochloride
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

advertisement

2022 Family Practice Notebook, LLC. Terms | Privacy | About | Site Map | Blog

Footer Site Logo